Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00362921 · ClinicalTrials.gov registry record · Phase 2
Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT00362921 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 52 participants.
The verdict
NCT00362921, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as Gliadel wafer and O6-benzylguanine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving Gliadel wafer together with O6-benzylguanine works in treating patients with recurrent glioblastoma multiforme.
Interventions
- DRUG Gliadel wafers in combination with O6-benzylguanine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2004-04 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00362921
The ClinicalTrials.gov registry entry for NCT00362921 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gliadel wafers in combination with O6-benzylguanine is the first listed.
NCT00362921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00362921 about?
NCT00362921 is a clinical study titled "Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme". RATIONALE: Drugs used in chemotherapy, such as Gliadel wafer and O6-benzylguanine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This p...
What is the current status of trial NCT00362921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2004-04. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00362921?
The interventions under investigation include: Gliadel wafers in combination with O6-benzylguanine (DRUG).
Who is sponsoring clinical trial NCT00362921?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.